Eva-maria Wicklein

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 26, 2026

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.

Journal: Neurology

Published: July 17, 2025

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.

Journal: Journal of neurology

Published: January 03, 2024

Body mass index as a predictor of MS activity and progression among participants in BENEFIT.

Body mass index as a predictor of MS activity and progression among participants in BENEFIT.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: January 07, 2022

Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT® Autoinjector: A Retrospective Cohort Study.

Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT® Autoinjector: A Retrospective Cohort Study.

Journal: Drugs - real world outcomes

Published: April 09, 2021

Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.

Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.

Journal: BMC neurology

Published: March 01, 2021

Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.

Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.

Journal: Therapeutic advances in neurological disorders

Published: September 18, 2019

Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.

Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.

Journal: Neurology

Published: June 29, 2019

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Journal: Brain imaging and behavior

Published: August 30, 2018

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: May 16, 2018

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 10, 2018

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Journal: Annals of neurology

Published: March 07, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026